← Back to Screener
Allarity Therapeutics, Inc. Common Stock (ALLR)
Price$1.24
Favorite Metrics
Price vs S&P 500 (26W)-30.46%
Price vs S&P 500 (4W)1.02%
Market Capitalization$19.77M
All Metrics
Book Value / Share (Quarterly)$0.61
P/TBV (Annual)0.44x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.92
Price vs S&P 500 (YTD)13.10%
EPS (TTM)$-0.80
10-Day Avg Trading Volume0.13M
EPS Excl Extra (TTM)$-0.80
EPS (Annual)$-0.78
ROI (Annual)-100.03%
Cash / Share (Quarterly)$0.92
ROA (Last FY)-61.51%
EBITD / Share (TTM)$-0.88
ROE (5Y Avg)-268.07%
Cash Flow / Share (Annual)$-0.92
P/B Ratio2.01x
P/B Ratio (Quarterly)1.76x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-12.89x
ROA (TTM)-49.92%
EPS Incl Extra (Annual)$-0.78
Current Ratio (Annual)2.13x
Quick Ratio (Quarterly)1.88x
3-Month Avg Trading Volume0.16M
52-Week Price Return74.34%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.62
P/S Ratio (Annual)61.79x
Asset Turnover (Annual)0.02x
52-Week High$2.35
EPS Excl Extra (Annual)$-0.78
CapEx CAGR (5Y)21.67%
26-Week Price Return-26.47%
Quick Ratio (Annual)1.88x
13-Week Price Return9.65%
Total Debt / Equity (Annual)0.14x
Current Ratio (Quarterly)2.13x
Enterprise Value$6.487
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-3509.69%
Cash / Share (Annual)$0.92
3-Month Return Std Dev88.76%
Net Income / Employee (TTM)$-2
ROE (Last FY)-114.28%
Net Interest Coverage (Annual)-7.32x
EPS Basic Excl Extra (Annual)$-0.78
Total Debt / Equity (Quarterly)0.14x
EPS Incl Extra (TTM)$-0.80
ROI (TTM)-77.19%
Revenue / Share (Annual)$0.02
Tangible BV / Share (Annual)$1.62
Price vs S&P 500 (52W)44.51%
Year-to-Date Return15.74%
5-Day Price Return8.70%
EPS Normalized (Annual)$-0.78
ROA (5Y Avg)-86.83%
Net Profit Margin (Annual)-3509.69%
Month-to-Date Return14.68%
Cash Flow / Share (TTM)$-30.29
EBITD / Share (Annual)$-0.88
Operating Margin (Annual)-3939.06%
LT Debt / Equity (Annual)0.57x
ROI (5Y Avg)-146.34%
LT Debt / Equity (Quarterly)0.57x
EPS Basic Excl Extra (TTM)$-0.80
P/TBV (Quarterly)0.44x
P/B Ratio (Annual)1.76x
Book Value / Share (Annual)$0.61
Price vs S&P 500 (13W)8.96%
Beta0.25x
Revenue / Share (TTM)$0.00
ROE (TTM)-85.29%
52-Week Low$0.66
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ALLRAllarity Therapeutics, Inc. Common Stock | — | — | — | — | $1.24 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Allarity Therapeutics is a clinical-stage pharmaceutical company developing stenoparib, an oral small-molecule inhibitor for advanced recurrent ovarian cancer. The company uses its proprietary Drug Response Predictor (DRP) technology to identify patients most likely to benefit from treatment, combining precision medicine with oncology. Operating in Denmark and the United States, Allarity is focused on addressing a significant unmet medical need in ovarian cancer treatment.